Healthcare -
Biotechnology - NASDAQ - US
$ 4.115
-8.42 %
$ 23.8 M
Market Cap
1.75
P/E
1. INTRINSIC VALUE
Balance Sheet
X4 Pharmaceuticals, Inc.
| Current Assets | 112 M |
| Cash & Short-Term Investments | 102 M |
| Receivables | 1.71 M |
| Other Current Assets | 8.4 M |
| Non-Current Assets | 34.3 M |
| Long-Term Investments | 0 |
| PP&E | 4.84 M |
| Other Non-Current Assets | 29.4 M |
| Current Liabilities | 32.9 M |
| Accounts Payable | 8.62 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 24.3 M |
| Non-Current Liabilities | 91.4 M |
| Long-Term Debt | 76.8 M |
| Other Non-Current Liabilities | 14.6 M |
EFFICIENCY
Earnings Waterfall
X4 Pharmaceuticals, Inc.
| Revenue | 2.56 M |
| Cost Of Revenue | 797 K |
| Gross Profit | 1.76 M |
| Operating Expenses | 38.2 M |
| Operating Income | -36.4 M |
| Other Expenses | 1.05 M |
| Net Income | -37.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
X4 Pharmaceuticals, Inc.
| Net Income | -37.4 M |
| Depreciation & Amortization | 796 K |
| Capital Expenditures | -326 K |
| Stock-Based Compensation | 8.2 M |
| Change in Working Capital | 0 |
| Others | -102 M |
| Free Cash Flow | -131 M |
Wall Street Analysts Price Targets
X4 Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for XFOR of $3.67 , with forecasts ranging from
a
low of
$3 to a high of $5 .
XFOR Lowest Price Target
Wall Street Target
3 USD
-27.10%
XFOR Average Price Target
Wall Street Target
3.67 USD
-10.90%
XFOR Highest Price Target
Wall Street Target
5 USD
21.51%
4. DIVIDEND
ANALYSIS
XFOR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
X4 Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
97.3 K USD 5
6-9 MONTHS
377 K USD 5
9-12 MONTHS
1.74 K USD 1
Bought
2.56 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
4.6 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 5,545 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
globenewswire.com
- 2 weeks ago
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor
globenewswire.com
- 1 month ago
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript
seekingalpha.com
- 1 month ago
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026
globenewswire.com
- 1 month ago
Top 3 Health Care Stocks That May Rocket Higher In April
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
benzinga.com
- 1 month ago
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025.
globenewswire.com
- 1 month ago
X4 Pharmaceuticals Announces Reverse Stock Split
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has determined to effect a one-for-thirty reverse stock split of the company's Common Stock, par value $0.001 per share. The reverse stock split will take effect at 12:01 a.m.
globenewswire.com
- 1 month ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 450,471 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
globenewswire.com
- 1 month ago
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
seekingalpha.com
- 2 months ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026
globenewswire.com
- 2 months ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.
globenewswire.com
- 3 months ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt
globenewswire.com
- 3 months ago
8. Profile
Summary
X4 Pharmaceuticals, Inc. XFOR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 23.8 M
Dividend Yield
0.00%
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Contact
61 North Beacon Street, Boston, MA, 02134
https://www.x4pharma.com
IPO
Date
Nov. 16, 2017
Employees
143
Officers
Dr. Paula Ragan Ph.D.
Chief Executive Officer, President & Director
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Mr. Adam S. Mostafa
Chief Financial Officer, Treasurer & Corporate Secretary
Ms. Natasha Thoren Esq.
Vice President, General Counsel & Compliance Officer
Mr. Mark Baldry M.B.A.
Chief Commercial Officer
Dr. Richard Peters M.D., Ph.D.
Founder
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporate Advisory Board
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.
Chief Medical Officer
Mr. Brian Bowersox
Vice President of Finance & Corporate Controller